repaglinide Side Effects
Also known as: Prandin
Analysis of 7,180 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
7,180
Death-Related
688
9.6% of reports
Hospitalizations
4,308
60.0% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 688 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 116 |
| LACTIC ACIDOSIS | 78 |
| ACUTE KIDNEY INJURY | 48 |
| HYPOGLYCAEMIA | 44 |
| DYSPNOEA | 42 |
| HYPOTENSION | 41 |
| SEPTIC SHOCK | 40 |
| PNEUMONIA | 37 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 34 |
| ASTHENIA | 32 |
| COMA | 30 |
| DIARRHOEA | 28 |
| RESPIRATORY FAILURE | 28 |
| DRUG INTERACTION | 27 |
| OFF LABEL USE | 26 |
| SHOCK HAEMORRHAGIC | 26 |
| RENAL FAILURE | 25 |
| CARDIAC ARREST | 24 |
| CONDITION AGGRAVATED | 24 |
| VOMITING | 24 |
Reactions in Hospitalization Reports
Top reactions in 4,308 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| HYPOGLYCAEMIA | 460 |
| ACUTE KIDNEY INJURY | 372 |
| DRUG INTERACTION | 308 |
| DIARRHOEA | 251 |
| DYSPNOEA | 202 |
| LACTIC ACIDOSIS | 200 |
| ANAEMIA | 187 |
| FALL | 183 |
| ASTHENIA | 182 |
| VOMITING | 160 |
| CONFUSIONAL STATE | 141 |
| PYREXIA | 141 |
| PNEUMONIA | 139 |
| NAUSEA | 131 |
| HYPOTENSION | 123 |
| DEHYDRATION | 121 |
| RENAL FAILURE | 120 |
| CARDIAC FAILURE | 118 |
| MALAISE | 118 |
| OFF LABEL USE | 115 |
Nearby — Related Medications
What the FAERS Data Reveals About repaglinide Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 7,180 voluntary reports linked to repaglinide and its brand equivalents (Prandin), spanning 2004 through 2025. Of those, 688 (9.6%) listed death as an outcome and 4,308 (60.0%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 46% were female and 54% male; age distribution skews toward 75+, with 2,547 reports in that bracket. The single most reported reaction is hypoglycaemia with 765 submissions, followed by acute kidney injury and drug interaction.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.